Related Experiment Video
Updated: Feb 15, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Nonmetastatic Castration-resistant Prostate Cancer: A Modern Perspective
Madeline Cancian1, Joseph F Renzulli2
1Department of Urology, Warren Alpert Medical School, Brown University, Providence, RI.
Abstract:
Nonmetastatic castration-resistant prostate cancer (nmCRPC) presents a challenge to urologists as currently there are no Food and Drug Administration-approved therapies. However, there are new imaging modalities, including fluciclovine positron emission tomography-computed tomography and Ga-PSMA (prostate specific membrane antigent) positron emission tomography-computed tomography, which are improving accuracy of diagnosis. With improved imaging, we are better able to target therapy. Today there are 3 ongoing clinical trials studying second-generation antiandrogens in nmCRPC, which hold the promise of a new treatment paradigm. In this article, we will review the new imaging techniques and the rationale behind novel treatment modalities in nmCRPC.
Insights
New imaging techniques improve diagnosis for nonmetastatic castration-resistant prostate cancer (nmCRPC). Ongoing trials explore novel therapies, including second-generation antiandrogens, offering a promising new treatment paradigm for nmCRPC.
Area of Science:
- Urology
- Oncology
- Radiology
Background:
- Nonmetastastic castration-resistant prostate cancer (nmCRPC) lacks FDA-approved therapies.
- Accurate diagnosis and staging are critical for effective treatment planning in nmCRPC.
Purpose of the Study:
- To review advancements in imaging for nmCRPC.
- To discuss the rationale for novel therapeutic strategies in nmCRPC.
Main Methods:
- Review of current literature on advanced imaging techniques.
- Analysis of ongoing clinical trials for nmCRPC treatments.
Main Results:
- Novel imaging modalities like fluciclovine PET-CT and Ga-PSMA PET-CT enhance diagnostic accuracy.
- Three clinical trials are investigating second-generation antiandrogens for nmCRPC.
Conclusions:
- Improved imaging facilitates precise therapeutic targeting in nmCRPC.
- Emerging therapies, particularly second-generation antiandrogens, represent a potential paradigm shift in nmCRPC management.
Related Concept Videos
Treatment Resistant Cancers
Modern Molecular Taxonomy
Psychodynamic Perspectives on Personality
Psychodynamic theorists argue that unconscious...
Social Cognitive Perspective on Personality
Criticisms of the Evolutionary Perspective
Evolutionary psychology provides one explanation for these findings, suggesting...
The Behavioral Perspective on Personality

